Novo Nordisk has contracted California-based biotech Septerna to develop oral pills that target G protein-coupled receptors.

Analysts believe each of the stocks below has the potential to at least double in price, although the three firms also carry varying levels of risk.

A report released Thursday said highly processed foods, exposure to chemicals and excessive use of prescription drugs are ...

They're brightly colored, packed in enticing boxes and often marketed as healthy -- but many cereals today are actually less ...